Palm Medical Centers Meets Growing Need for Senior Healthcare in Central Florida with New Zephyrhills Office to Open in November

Palm Medical Centers (“PMC”), an MBF Healthcare Partners II, L.P. (“MBF”) portfolio company, continues its rapid strategic growth in a quickly evolving senior healthcare market with the announcement of a second office opening in Pasco County in November. Located in Zephyrhills, the center is PMC’s 19th clinic location throughout Florida. It is one of 12 clinics serving the booming Central Florida region and the 5th clinic addition for PMC during 2021.

“The expansion in Pasco County is significant because quality care will now be available to an underserved and flourishing population,” said Chandravadan J. Patel, M.D., Chief Medical Officer with Palm Medical Centers. “Accessible healthcare is essential in meeting the needs of patients, and our business model shows how a practice can be exported into an important geographic region to deliver much-needed quality care more efficiently. We will be able to provide more care for more patients, which means better health outcomes in that region.”

Located at 6836 Medical View Lane, the office in Zephyrhills will be under the medical direction of Marina Kulick, M.D., an established family practitioner and one of 42 primary care providers employed by PMC. The office, open from 8 a.m. to 5 p.m., Monday through Friday, will contain eight clinical exam rooms.

In addition to primary care services, EKGs, lung function tests, and other diagnostics, the Zephyrhills location will also offer in-house podiatry care once a week, as well as much-needed transportation services. Every patient enrolled in a Medicare Advantage plan will receive a comprehensive annual wellness visit and the office will also be offering telehealth and virtual visits for patient convenience. Tele-Psych services for virtual psychiatry appointments will also be offered.

“Our expansion provides seniors in the rapidly growing Pasco County region with increased accessibility to quality healthcare, as well as many health options to help them age well and lead a healthier lifestyle,” noted PMC Chief Executive Officer Fowad Choudhry. “The senior market continues to grow year-over-year, and we are there to meet the need for primary care in the area.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”